Abstract
Purpose
The aim of this trial was to investigate the efficacy and safety of cisplatin (P) and irinotecan (I) (PI) alternating with doxorubicin (A), cyclophosphamide (C) and etoposide (E) (ACE) in patients with extensive-disease small-cell lung cancer (ED-SCLC).
Patients and Methods
Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m2 on day 1; I: 60 mg/m2/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m2 on day 1; C: 750 mg/m2 on day 1; E 80 mg/m2/day on days 1–3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation.
Results
In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15%) complete responses, were observed in 25 patients (93%). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4%, respectively. Febrile neutropenia occurred in 30% of patients. Diarrhea was mild (grade 3–4; 4%). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1%, respectively.
Conclusions
These results indicate the PI–ACE regimen to have promising activity against ED-SCLC with moderate toxicities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Johnson BE (2002) Management of small cell lung cancer. Clin Chest Med 23(1):225–239
Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63(11–12):1727–1733
Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83(12):855–861
Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10(2):282–291
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2):85–91
Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M, Moriyama G, Mizutani H, Hibino S, Gemma A, Okano T, Shibuya M, Kudoh S (2004) Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44(1):121–127
Bunn PA Jr, Greco FA, Einhorn L (1986) Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol 13(Suppl 3):45–53
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214
Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16(3):1068–1074
Longo DL, Duffey PL, DeVita VT Jr, Wesley MN, Hubbard SM, Young RC (1991) The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9(11):2042–2051
Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24(13):2038–43
Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81(22):1732–1735
Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50(24):7962–7965
Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M (1998) Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16(10):3329–3334
Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ, DeBoer G (1985) Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small cell lung cancer. J Clin Oncol 3(1):65–71
Acknowledgments
We wish to thank Drs. Akihiro Bessho and Naoyuki Nogami (National Hospital Organization Shikoku Cancer Center), Kenichi Gemba (Okayama Rousai Hospital), Tomonori Moritaka and Takushi Kitajima (Ehime Prefectural Central Hospital), Tadashi Maeda, Keisuke Aoe and Hideki Katayama (National Hospital Organization National Sanyo Hospital), Junichiro Hiyama (Kure Kyosai Hospital) and Hiroaki Miyamoto (Okayama City Hospital) for their support and the provision of data for our study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tabata, M., Kiura, K., Okimoto, N. et al. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Cancer Chemother Pharmacol 60, 1–6 (2007). https://doi.org/10.1007/s00280-006-0336-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-006-0336-0